Haemonetics elects Carlyle healthcare exec to board, shareholders approve equity plan expansion

Filed July 28, 2026 · Period ending July 24, 2026 · ~1 min read

Key Changes

• medium

  Martin Madaus, Senior Operating Executive at The Carlyle Group with 30+ years in diagnostics and life sciences, elected to board effective July 24, 2026. Previously led turnarounds at Ortho Clinical Diagnostics and Millipore Corporation.

  Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
• medium

  Shareholders approved 4,680,000 additional shares for the Long-Term Incentive Plan and extended the plan through 2036 (94.8% of votes cast, 83.0% of shares outstanding).

  Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR →
• low

  All eight directors elected with 97.4%–99.7% support; say-on-pay approved with 98.6% support; Ernst & Young ratified as auditor with 98.3% support.

  Item 5.07 — Submission of Matters to a Vote of Security Holders verify on EDGAR →